Resolution re. Lab 21 HSE Prosecution
Lab 21 subsidiary fined £52,000 by court for health and safety violations at Axminster site.
- Fine ordered £52,000
Select text to share a quote on X · sign in to keep highlights & notes in your NCYT notes
Paris, France, and Manchester, UK - 12 September 2025 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, provides an update with regards to the Health and Safety Executive ("HSE") prosecution first announced on 21 January 2025.
On 11 September 2025, a sentencing hearing took place in respect of legal proceedings brought against Lab 21 Healthcare Ltd ("Lab 21"), a non-trading subsidiary of Novacyt, in relation to Lab 21's site based at Axminster, Devon for the use of biological agents at the site. As announced on 18 March 2025, Lab 21 pleaded guilty at Exeter Magistrates Court to health and safety charges relating to the historical operation at the site, between June 2018 and April 2019. The court granted full recognition for an early guilty plea with Lab 21 being ordered to pay a fine of £52,000.
This fine will be paid from existing cash resources and does not materially affect the Group financial position.
This now concludes this process, with no further liability or legal action expected in relation to this case.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.